Rovin Capital UT ADV Sells 3,257 Shares of Pfizer Inc. (NYSE:PFE)

Rovin Capital UT ADV reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 24,204 shares of the biopharmaceutical company’s stock after selling 3,257 shares during the period. Rovin Capital UT ADV’s holdings in Pfizer were worth $642,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP bought a new stake in Pfizer in the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the third quarter worth approximately $35,000. Joseph Group Capital Management grew its position in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Kennebec Savings Bank purchased a new position in shares of Pfizer during the third quarter worth approximately $50,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.6 %

Shares of Pfizer stock opened at $26.25 on Thursday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market cap of $148.76 billion, a price-to-earnings ratio of 35.47, a PEG ratio of 0.64 and a beta of 0.64. The company has a 50-day moving average of $26.13 and a 200 day moving average of $28.03. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.